jidinum 100 mg filmdragerad tablett
medochemie ltd - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 100 mg - sitagliptinhydrokloridmonohydrat 113,4 mg aktiv substans
jidinum 50 mg filmdragerad tablett
medochemie ltd - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg - sitagliptinhydrokloridmonohydrat 56,7 mg aktiv substans
frekidir 100 mg filmdragerad tablett
pharmathen s.a. - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 100 mg - sitagliptinhydrokloridmonohydrat 113,36 mg aktiv substans
frekidir 50 mg filmdragerad tablett
pharmathen s.a. - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg - sitagliptinhydrokloridmonohydrat 56,68 mg aktiv substans
frekidir 25 mg filmdragerad tablett
pharmathen s.a. - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 25 mg - sitagliptinhydrokloridmonohydrat 28,34 mg aktiv substans
jivolar 50 mg/850 mg filmdragerad tablett
medochemie ltd - metforminhydroklorid; sitagliptinfosfatmonohydrat - filmdragerad tablett - 50 mg/850 mg - sitagliptinfosfatmonohydrat 64,25 mg aktiv substans; metforminhydroklorid 850 mg aktiv substans; natriumlaurilsulfat hjälpämne
mifomet 50 mg/850 mg filmdragerad tablett
bausch health ireland ltd - metforminhydroklorid; sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg/850 mg - sitagliptinhydrokloridmonohydrat 54,47 mg aktiv substans; natriumlaurilsulfat hjälpämne; metforminhydroklorid 850 mg aktiv substans
jivolar 50 mg/1000 mg filmdragerad tablett
medochemie ltd - metforminhydroklorid; sitagliptinfosfatmonohydrat - filmdragerad tablett - 50 mg/1000 mg - natriumlaurilsulfat hjälpämne; metforminhydroklorid 1000 mg aktiv substans; sitagliptinfosfatmonohydrat 64,25 mg aktiv substans
trulicity
eli lilly nederland b.v. - dulaglutide - diabetes mellitus, typ 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. för att studera resultaten med avseende kombinationer av effekter på glykemisk kontroll och kardiovaskulära händelser, och de populationer som studeras, se avsnitt 4. 4, 4. 5 och 5.
segluromet
merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.